Kain Capital Opens New Office in Manhattan’s Financial District
Healthcare Private Equity Firm Builds for Growth with Renewed New York Presence NEW YORK–(BUSINESS WIRE)–Kain…
Month: March 2023
FinWise Bancorp Promotes James Noone to President of FinWise Bank
MURRAY, Utah–(BUSINESS WIRE)–FinWise Bank, a subsidiary of FinWise Bancorp, announced today that the Board of…
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
Dr. Myers brings extensive executive experience leading the development of clinical programs through US and…
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
Management to host conference call and webcast at 4:30 p.m. ET IRVINE, Calif., March 23,…
PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics”…
Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
Publication of annual report for financial year 2022 Annual Shareholders’ Meeting proposed resolutions include re–appointment of…
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA…
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA…
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA…
Candidly Wins “Best Student Loan Management Platform” Designation in 7th Annual FinTech Breakthrough Awards Program
Prestigious International Awards Program Recognizes Outstanding Financial Technology Products And Companies NEW YORK–(BUSINESS WIRE)–Candidly, the…
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering…
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering…
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering…
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and…
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and…
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and…
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple…
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple…
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple…